Dana-Farber CEO Outlines Ambitious Vision as Cancer Institute Separates from Mass General Brigham and Plans New Hospital

Dana-Farber Cancer Institute CEO Benjamin Ebert is charting a transformative new course for one of the nation’s most prestigious cancer research and treatment centers, detailing plans to disentangle the institution from its longtime partner Mass General Brigham while simultaneously pursuing the construction of a new cancer hospital. The dual undertaking represents one of the most significant structural shifts in the history of Boston’s renowned medical corridor and carries far-reaching implications for cancer patients, biomedical research, and the economics of academic medicine in the United States.

The relationship between Dana-Farber and Mass General Brigham — the sprawling health system formerly known as Partners HealthCare — has been one of the most consequential partnerships in American academic medicine. Under a clinical affiliation dating back decades, Dana-Farber physicians provided inpatient cancer care at Brigham and Women’s Hospital through the jointly branded Dana-Farber/Brigham Cancer Center. The arrangement allowed Dana-Farber, which historically operated as a largely outpatient-focused research institute, to offer its patients access to full hospital services including surgical oncology, intensive care, and emergency medicine. However, the deeply intertwined operational structures also created layers of administrative complexity, shared billing systems, overlapping governance, and joint clinical programs that now must be carefully separated. Ebert has described the untangling process as painstaking but necessary to allow Dana-Farber to control its own clinical destiny, set its own strategic priorities, and build the kind of vertically integrated cancer center that can compete with peers like MD Anderson Cancer Center in Houston and Memorial Sloan Kettering in New York.

The planned new hospital is the physical embodiment of this independence. Dana-Farber has long lacked its own inpatient facility, a gap that distinguished it from many of its peer institutions. Building a dedicated cancer hospital would give the institute direct control over surgical suites, inpatient beds, and perioperative care — functions currently managed through the Brigham partnership. Major cancer centers across the country have been investing heavily in new facilities in recent years. MD Anderson completed a $250 million surgical tower, and Memorial Sloan Kettering opened a major new ambulatory care center. These investments reflect the rapidly evolving landscape of cancer treatment, where precision medicine, cell and gene therapies, and proton beam therapy demand specialized infrastructure. For Dana-Farber, the new hospital is not merely a construction project — it is a bet that controlling the full continuum of cancer care under one institutional roof will improve outcomes, accelerate research translation, and attract top talent in an increasingly competitive recruitment environment.

The separation also arrives at a turbulent moment for biomedical research institutions. Federal funding from the National Institutes of Health, the lifeblood of academic research centers like Dana-Farber, has faced unprecedented uncertainty amid political debates over government spending and scientific priorities. At the same time, the economics of hospital construction have been strained by inflation, rising interest rates, and supply chain pressures that have driven up building costs by an estimated 20 to 30 percent since 2020. Ebert will need to navigate these financial headwinds while maintaining donor confidence — Dana-Farber has historically relied on robust philanthropic support, including its iconic Jimmy Fund campaigns. The institute raised over $700 million in a capital campaign completed in recent years, and a new hospital project could require fundraising on an even larger scale.

Looking ahead, several critical milestones will determine whether Ebert’s vision succeeds. Regulatory approvals from the Massachusetts Department of Public Health, including a Determination of Need filing, will be required before construction can proceed. The institute must also negotiate transitional agreements with Mass General Brigham to ensure continuity of care during the separation, particularly for complex surgical oncology patients. Workforce implications are significant as well — physicians, nurses, and staff currently employed or jointly appointed through the Brigham affiliation will need clarity on their future roles. Observers of the Boston healthcare market will be watching closely to see whether this divorce ultimately strengthens both institutions or introduces disruptive gaps in the region’s cancer care network.